New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

Gilead Sciences, Inc. presented new data supporting Sunlenca® as an important treatment option for adults with multi-drug resistant HIV who have extensive treatment history.